This is a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to
evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with
Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract
infection (URTI) symptoms who test positive for respiratory syncytial virus (RSV) and
negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable
asthma or chronic obstructive pulmonary disease (COPD) will be allowed in the study.
Approximately 70 subjects will be enrolled in this Phase 2b, randomized, double-blind,
placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of
acute URTI with confirmed RSV infection in ambulatory adult subjects.
For each subject, the duration of study participation will be approximately 2 weeks and will
consist of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days
after last dose).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.